Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...
MedPage Today on MSN1d
Year in Review: Early Breast CancerNews in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
News Medical on MSN16h
New treatment combination improves outcomes for small cell bladder and prostate cancer patientsA research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...
Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...
MedPage Today on MSN19h
Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyMedian overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback